Search This Blog

Thursday, May 22, 2025

Bayer (BAYZF) Gains Approval for Eylea 8 mg in China

 

  • Bayer AG's Eylea 8 mg gains approval in China for treating age-related macular degeneration.
  • The approval follows positive results from late-stage trials.
  • Developed in collaboration with Regeneron, Eylea offers extended treatment intervals.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)